Analysts Set Repligen Co. (NASDAQ:RGEN) Price Target at $185.20

Shares of Repligen Co. (NASDAQ:RGEN) have earned a consensus rating of “Moderate Buy” from the thirteen research firms that are presently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $185.20.

Several brokerages have weighed in on RGEN. StockNews.com downgraded Repligen from a “hold” rating to a “sell” rating in a report on Thursday. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th. Finally, Wells Fargo & Company assumed coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company.

Repligen Stock Down 1.4 %

Shares of RGEN opened at $144.46 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock has a market capitalization of $8.09 billion, a PE ratio of -390.42, a P/E/G ratio of 4.64 and a beta of 0.96. The company’s 50-day simple moving average is $144.18 and its 200-day simple moving average is $141.67. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same quarter last year, the company posted $0.23 EPS. The firm’s revenue was up 9.7% compared to the same quarter last year. Analysts forecast that Repligen will post 1.54 earnings per share for the current fiscal year.

Institutional Trading of Repligen

Hedge funds and other institutional investors have recently made changes to their positions in the company. Assenagon Asset Management S.A. lifted its stake in Repligen by 937.8% in the second quarter. Assenagon Asset Management S.A. now owns 30,189 shares of the biotechnology company’s stock valued at $3,806,000 after buying an additional 27,280 shares during the last quarter. Raymond James & Associates increased its holdings in shares of Repligen by 3.7% in the 2nd quarter. Raymond James & Associates now owns 55,119 shares of the biotechnology company’s stock valued at $6,948,000 after acquiring an additional 1,951 shares during the period. Fifth Third Bancorp raised its position in Repligen by 6.4% in the 2nd quarter. Fifth Third Bancorp now owns 3,096 shares of the biotechnology company’s stock valued at $390,000 after purchasing an additional 187 shares during the last quarter. Fifth Third Wealth Advisors LLC acquired a new stake in Repligen during the 2nd quarter worth $273,000. Finally, Slow Capital Inc. grew its position in Repligen by 10.7% during the 2nd quarter. Slow Capital Inc. now owns 16,165 shares of the biotechnology company’s stock worth $2,038,000 after purchasing an additional 1,558 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.